Research
Hormonal
Pharmacological treatments, particularly GLP-1 agonists, have shown promising results but are limited by lack of cost coverage.
Practitioners should be aware of the potential benefits of GLP-1 agonists while considering the financial implications for patients.
StrongQualifiesmedium confidence
Pharmakologische Behandlungen, insbesondere GLP-1-Agonisten, haben vielversprechende Ergebnisse gezeigt. Diese können jedoch aufgrund der fehlenden Kostenübernahme nur eingeschränkt eingesetzt werden.
Why this rating
The abstract provides a clear statement on the effectiveness and limitations of pharmacological treatments.
Source
Interdisziplinäre Adipositastherapie
Susanne Blank et al. · Adipositas - Ursachen Folgeerkrankungen Therapie · 2024
DOI 10.1055/a-2340-0932
other
Read the paper DOI resolved against Crossref · corpus check 2026-06-10
More from this paper
Related findings · Hormonal
- Initial treatment for type 2 diabetes should be a combination of metformin and either an SGLT-2 inhibitor or a GLP-1 receptor agonist to achieve cardiorenal protection, rather than monotherapy or older agents like sulfonylureas.Strong
- For patients with specific monogenic obesity syndromes (leptin deficiency, POMC/PCSK1/LEPR mutations), targeted pharmacotherapy (recombinant leptin or setmelanotide) is highly effective and should be prioritized, unlike in polygenic obesity.Strong
- Continued weekly administration of 2.4 mg subcutaneous semaglutide prevents weight regain and promotes further weight loss in adults with overweight or obesity, whereas switching to placebo results in significant weight regain.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →